Drug intelligence / Profile preview

IMC-2013

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

IMC-2013 is a stem cell therapy candidate being developed by ImmuneCyte Life Sciences for the treatment of osteoarthritis (OA). The therapy is produced using the company's proprietary AutoSTEM platform, which is an automated, large-scale manufacturing system designed to ensure the standardized production of high-quality stem cells. IMC-2013 aims to address the underlying pathology of osteoarthritis by leveraging the regenerative and anti-inflammatory properties of stem cells to repair joint tissue and alleviate chronic pain. It is currently in the preclinical and pilot stages of development.

Beyond the preview

Go deeper on IMC-2013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-2013.

Explore the full profile